A microinfusor device for the delivery of therapeutic levels of peptides and macromolecules

Journal of Controlled Release

Volumn 46, Issue 1-2, 1997, Pages 107-116

  Meehan, E ^a   Gross, Y ^b   Davidson, D ^b   Martin, M ^a   Tsals, I ^b  

^a ELAN PHARMACEUTICALS   (United States)

^b Athlone Co   (Ireland)

Author keywords

Drug delivery; Heparin; Macromolecules; Medipad; Microinfusor; Morphine; Subcutaneous

Indexed keywords

HEPARIN; MORPHINE;

AREA UNDER THE CURVE; CONFERENCE PAPER; DEVICE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; HUMAN; HUMAN EXPERIMENT; INFUSION SYSTEM; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VOLUNTEER;

EID: 0031039379     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(96)01608-2     Document Type: Conference Paper

References (25)

1. J. Grindley and J. Ogden, Forecasting the future for protein drugs, Scrip Mag. Nov., (1995) 53-56.
2. P. Langguth, H.P. Merkle and G.L. Amidon, Oral absorption of peptides; The effect of absorption site and enzyme inhibition on the systemic availability of Metkephamid, Pharm. Res., 11 (1994) 528-535.
3. P. Couvreur and F. Puisieux, Nano- and microparticles for the delivery of polypeptides and proteins, Adv. Drug Delivery Rev., 10 (1993) 141-162.
4. Y. Gross and J.G. Kelly, Intradermal drug delivery device and method for the intradermal delivery of drugs, U.S. Patent 5 527 288, June 18, 1996.
5. E. Meehan, T. Nolan, Y. Gross and J.G. Kelly, In-vivo intradermal delivery of peptides, Pharm. Res., 11 (1994) S-180.
6. O.K. Gourlay, D.A. Cherry and M.J. Cousins, A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer, Pain, 25 (1986) 297-312.
7. R.D. Rosenbery and P.S. Damus, The purification and mechanism of action of human antithrombin-heparin cofactor, J. Biol. Chem., 248 (1973) 6490-6505.
8. F.A. Ofosu, M.A. Blajchman and J. Hirsch, The inhibition by heparin of the intrinsic pathway activation of factor X in the absence of antihrombin III, Throm. Res., 20 (1980) 391-403.
9. C. Dollery, Heparin sodium and heparin calcium, In A.R. Boobis, D. Burley, D.M. Davies, D.S. Davies, P.I. Harrison, M. Le Rome, B.K. Park and L.I. Goldbery (Eds.), Therapeutic Drugs, Churchill Livingstone, London, 1991.
10. V.A. Barss, P.A Schwartz, M.F. Greene, M. Phillippe, D. Saltzman and F.D. Frigoletto, Use of the subcutaneous heparin pump during pregnancy, J. Reprod. Med., 30 (1985) 899-902.
11. J. Rabinovici, A. Mani, G. Barkai, H. Hod, Y. Frenkel and S. Mashiach. Long term ambulatory anticougulation by constant subcutaneous heparin infusion in pregnancy, Brit. J. Obs. Gyn., 94 (1987) 89-91.
12. J.L. Mason, S.P Ashmore and A.R. Ditkenhead, Simple method for the determination of morphine and its active glucuronide metabolites in human plasma by high performance liquid chromatography with electrochemical detection, J. Chromatogr., 570 (1991) 191-197.
13. A.J. Bircher, R. Fluckiger and S.A. Buchner, Eczematous infiltrated plaques to subcutaneous heparin: a type IV allergic reaction, Brit. J. Dermatol., 123 (1990) 507-514.
14. C. Kroom, A. De Boer, J.M. Kroon, H.C. Schoenmaker, F.J.M. Meer and A.F. Cohen, Influence of skinfold thickness on heparin absorption, Lancet, 337 (1991) 945-946.
15. A. Diquelou, D. Dupouy, R. Cariou, K.S. Sakariassen, B. Boneu and Y. Cadroy, A comparative study of the anti-coagulant and antithrombotic effects of unfractionated heparin and a low molecular weight heparin (Fraxiparine) in an experimental model of human venous thrombosis, Thromb. Haem., 74 (1995) 1286-1292.
16. D.A. Lane, J. Denton, A.M. Flynn, L. Thunberg and U. Lindahl, Anticoagulant activities of heparin oligosaccharides and their neutralisation by platelet factor, Biochem. J., 218 (1984) 725-732.
17. D.A. Lane, G. Pejler, A.M. Flynn, E.A. Thompson and U. Lindahl, Neutralisation of heparin related saccharides by histidine-rich glycoprotein and platelet factor 4, J. Biol. Chem., 261 (1986) 3980-3986.
18. P. Bianchini P, G.L. Bergonzin, B. Parma and B. Osima, Relationship between plasma antifactor Xa activity and the antithrombotic activity of heparins of different molecular mass, Haemostasis, 25 (1995) 288-298.
19. M. Samama, P. Bernard, U.P. Bonnardot, E. Tissot, Y. Lanson and S. Combe-Tanzal, Low molecular weight heparin (enoxaparine) compared with unfractionated heparin thrice a day in prevention of post operative thrombosis, Brit. J. Surgery, 75 (1988) 128-131.
20. M.N. Leoine, A. Planes, J. Hirsch, M. Goodyear, N. Vochelle and M. Gent, The relationship between the antifactor Xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement, Thromb. Haem., 62 (1989) 940-944.
21. R. Hull, T. Delmore and C. Carter, Adjusted subcutaneous heparin versus warfarin sodium in the long term treatment of venous thrombosis, New Engl. J. Med., 306 (1982) 189-194.
22. R.J. Cipolle, R.D. Seifert, B.A. Neilan, D.E. Zaske and E. Haus, Heparin kinetics: Variables related to disposition and dosage, Clin. Pharmacol. Ther., 29 (1981) 387-393.
23. M. Verstraete, Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins, Drugs, 40 (1990) 498-530.
24. B. Dahlstrom, A. Tamsen, L. Paalzow and P. Hartvid, Patient controlled analgesic therapy, Part IV: Pharmacokinetics and analgesic plasma concentrations of morphine, Clin. Pharmacokinet., 7 (1982) 266-279.
25. A. Tamsen, Comparison of patient controlled analgesia with constant infusion and intermittent intramuscular regimens, In M. Harmer, M. Rosen and M.D. Vickers (Eds.), Patient-controlled analgesia, Blackwell Scientific Publications, Oxford, 1985, pp. 111-125.